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Abstract
Background: Currently, no suitable biomarkers for the early detection of pancreatic cancer (PC) are
available. Proteins present in the serum could reflect a state of the disease. In this study, these profiles
as a diagnostic marker for PC were evaluated.
Methods: Serum samples were obtained from PC patients (n = 50 calibration set, n = 39 validation set)
and healthy volunteers (n = 110 and n = 75 respectively) according to a uniform standardized collection
and processing protocol. For peptide and protein isolation, automated solid-phase extraction (SPE) with
Weak Cation Exchange (WCX) magnetic beads (MB) was performed using a 96-channel liquid handling
platform. Protein profiles were obtained by mass spectrometry (MS) and evaluated by linear discriminant
analysis with double cross-validation.
Results: A discriminating profile for PC has been identified, with a sensitivity of 78% and a specificity of
89% in the calibration set with an area under the curve (AUC) of 90%. These results were validated with
a sensitivity of 74% and a specificity of 91% (AUC 90%).
Conclusion: Serum profiles of healthy controls and PC can be discrimated between. Further research is
warranted to evaluate specificity and whether this biosignature can be used for early detection in a high
risk population.
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Introduction
Although pancreatic cancer (PC) has an annual incidence of only
8.2 cases per 100 000 males and of 5.4 cases per 100 000 females, it
is the fifth (male) and fourth (female) leading cause of cancer death
in developed countries.1 Patients with PC have an extremely poor
prognosis with an overall 5-year survival rate of less than 5%.2When
a surgical resection is possible, 5-year survival rates increase to
approximately 25%, but unfortunately most tumours are at an
advanced stage when diagnosed.3,4 Delays in diagnosis are often
caused by the lack of specific symptoms for early cancers, such as
pain, jaundice and weight loss. Biomarkers might be an additional
tool for diagnostics next to currently available imaging techniques.
Themostly studied available clinical serumbiomarker carbohydrate
antigen 19-9 (CA19-9) has a sensitivity of 80% and a specificity of
90% but misses the appropriate sensitivity and specificity for small,
resectable cancers.5 Moreover, CA19-9 is often elevated in benign
cholangitis, pancreatitis and other cancers, and therefore lacks the
specificity for detecting potentially curable lesions. At this moment,
the use of CA19-9 is only recommended for follow-up. Currently,
only imaging techniques such as ultrasound (transcutaneous or
endoscopic), computed tomography (CT) scan, endoscopic retro-
grade cholangiopancreatography (ERCP), magnetic resonance
imaging (MRI) and MR cholangiopancreatography (MRCP) are
used for the diagnosis and staging of the pancreatic disease.
Chronic pancreatitis could mimic PC at diagnostics and
hampers patient selection for a pancreaticoduodenectomy. For
these patients a new biomarker that discriminates between
pancreatitis and cancer could be of great value.
It has been estimated that 5% to 10% of PC cases are associated
with an inherited predisposition. Tumour syndromes associated
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with an increased risk of PC include Peutz–Jeghers syndrome,
familial atypical multiple mole melanoma (FAMMM), hereditary
breast cancer (BRCA2 mutation carriers) and possibly Lynch
syndrome. The lifetime risk of PC varies between 5% in BRCA2
mutation carriers and 36% in patients with Peutz–Jeghers
syndrome.6–9 For this patient group, early detection is of para-
mount importance as the prognosis is usually poor when diagno-
sis follows symptoms. No studies for the early detection in this
specific high-risk group using CA19-9 have been performed. At
this time this is only possible through imaging surveillance.10
Therefore, there is an urgent need for new and better biomarkers
for PC.
A sensitive and specific option could be the use of proteomic
serum biomarkers. During transformation of a normal cell into a
neoplastic cell, distinct changes occur at the protein level which
may affect cellular function.11 Therefore, proteins are considered
promising targets for biomarker discovery. Mass spectrometry
(MS) has become the method of choice for protein analysis in
serum.12,13 Provided standardized sample workup, MS measure-
ment, data processing and evaluation, peptide and protein profiles
are highly reproducible.14 With respect to speed and automation
strategies needed for high-throughput screening, matrix-assisted
laser desorption/ionization-time of flight (MALDI-TOF) MS
workflows remain unrivalled.12,15,16 As human body fluids such
as serum are highly complex a suitable ‘clean-up’ procedure is
required.17 Based on the physicochemical properties of protein
separation techniques, magnetic beads (MB) have been function-
alized accordingly [e.g. Weak Cation Exchange (WCX)]. These
beads are not only suited for clean-up, but also enrich subsets of
peptides and proteins and can thus contribute to the sensitivity of
the assay.18 The present serum peptide/protein capture procedure
has been fully automated with a liquid handling robot, such as a
96-channel Hamilton STARplus® platform (Hamilton, Bonaduz,
Switzerland). This ensures reproducibility and allows high-
throughput screening which is essential for large-scale disease
profiling studies.19,20 In the last decade, multiple studies have been
carried out using amagnetic bead-basedmethod for offline serum
peptide/protein capture and MALDI-TOF-MS readout.14,21–25
For PC, several proteomic studies have been performed since
the introduction of protein profiling in 2002 by Petricoin et al,26
all with different fractionation platforms and type of MS.27–33 For
example, Koopman et al.34 used a surface enhanced laser
desorption/ionization (SELDI)-TOF approach combined with
WCX and metal affinity protein chips as the solid-phase extrac-
tion (SPE) method to discriminate between patient groups with a
sensitivity of 78% and a specificity of 97%. No study has been
published using a combination of WCX MB and MALDI-TOF.
For this study, a MALDI-TOF serum platform in combination
with functionalizedWCXMB was used to generate serum protein
profiles in a first attempt to differentiate between PC patients and
healthy controls in a stringent sample handling and high through-
put and automated processing protocol. The obtained discrimi-
nating profile was validated in a second case–control group.
Material and methods
Patients
Blood samples were obtained from 50 patients with PC prior to
surgery, and from 110 (age-and gender-matched) healthy volun-
teers at the outpatient clinic of the Leiden University Medical
Center (LUMC), theNetherlands fromOctober 2002 until Decem-
ber 2008. Healthy volunteers were partners or accompanying
persons of included patients. For the validation set, blood samples
were obtained from 39 patients and 75 healthy (age and gender
matched) volunteers, included from January 2009 until July 2010.
Patients were selected candidates for curative surgery; this meant
that no patients with primary irresectable tumours were included.
All surgical specimens were examined according to routine histo-
logical evaluation and the extent of the tumour spreadwas assessed
by TNM (TNM Classification of Malignant Tumours) classifica-
tion. Furthermore, the tumourmarker CA-19.9 was noted if deter-
mined pre-operatively. An Elecsys CA19-9 tumour marker assay
based on the monoclonal 116-NS 19-9 antibody (Roche Diagnos-
tics GmbH,Mannheim, Germany) was used. This tumour marker
has a normal reference value of 0.0–27.9 U/ml (95th percentile).
Informed consent was obtained from all subjects and the studywas
approved by the Medical Ethical Committee of the LUMC.
Blood collection
Samples from both the calibration set and the validation set were
collected and processed according a standardized protocol:14 in
short, all blood samples were drawn by antecubital venapuncture
while the individuals were seated and had not been fasting prior to
any invasive procedure. The samples were collected in an 8.5-cc
Serum Separator Vacutainer Tube (BD Diagnostics, Plymouth,
UK) and maximally within 4 h at room temperature centrifuged
at 1000 g for 10 min.14 The samples were then distributed into
sterile 500-ml barcode labelled polypropylene aliquots (Thermo
Fisher Scientific, Hudson, NH, USA) and stored at -80°C.
Sample processing
Aliquotting and storage
An overview of the processing platform of the serum samples,
MALDI-TOF profiles and data is given in Fig. 1. All serum
samples were thawed on ice once and randomly placed in barcode
labelled racks in an 8-channel Hamilton STAR® pipetting robot
(Hamilton) for automated aliquotting in 60-ml daughter tubes.
The aliquots were stored at -80°C until further sample processing.
The processing steps for the validation set were identical to those
for the calibration set.
WCX-MB sample work up
The isolation of proteins from serum was performed using a
commercially available kit based on magnetic bead purification
(Bruker Daltonics, Bremen, Germany). The WCX MB were
applied according to the manufacturer’s instructions with further
optimization to allow implementation on a 96-channel Hamilton
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STARplus® pipetting robot (Hamilton). Binding- and washing
buffers were used from the kit. In the final pipetting steps, peptides
and proteins were first eluted from the beads using a 130-mM
ammoniumhydroxide solution (J.T. Baker, Deventer, the Nether-
lands) and then stabilized with a 3% trifluoro acetic acid solution
(Sigma, St Louis, MO, USA).
MALDI spotting
Two microlitres of each stabilized eluate was transferred into a
384-well microtitration plate to carry out mixing with MALDI
matrix (a-cyano-4-hydroxycinnamic acid from Bruker Daltonics,
3 mg/ml in acetone/ethanol 1:2). One microlitre of this mixture
was spotted in quadruplicate onto a MALDI 600 mm Anchor-
Chip™ plate (Bruker Daltonics).
Profile processing
MALDI-TOF measurement
MALDI-TOF mass spectra (profiles) of the peptides and proteins
were obtained using a positive-ion linear mode acquisition on an
Ultraflex II TOF/TOF spectrometer (Bruker Daltonics) equipped
with a SCOUT ion source and controlled by the Flexcontrol 3.0
software package (Bruker Daltonics). Ions generated by the
Smartbeam™ laser were accelerated to 25 kV and mass analysed
from 960 to 11 024 Da. Each mass spectrum represents the sum of
20 mass spectra obtained from 60 laser shots. All unprocessed
spectra were exported from the Ultraflex II in standard 8-bit
binary ASCII format.
Baseline correction and alignment of profiles
For optimal data analysis, all profiles generated after sample
workup with WCX MB (further referred to as WCX profiles)
required baseline correction followed by alignment. First, a base-
line subtraction of all profiles was performed using the baseline
subtraction tool of FlexAnalysis 3.0. Second, to perform the
alignment of WCX profiles from one MALDI target plate at least
three peptides at different m/z values were essential for internal
calibration. In order to compensate for the possible absence of
one or two peptides in a spectrum, the following seven peptides
were selected based on a manual inspection of a few spectra,
namely at m/z 1866.1, 3158.0, 4643.6, 5903.7, 6631.1, 7765.5 and
9290.9.22,35
Peak selection and -quantification
Protein and/or peptide signals in WCX profiles were quantified as
follows. First, based on visual inspection of the profiles, 113 peaks
were selected for further analysis. To this end, a so-called reference
file was compiled including a certain m/z window for each signal
or peak. This m/z window reflected the peak width and varied
from 5–30 Da. Three examples of the selected peaks are shown in
Fig. 2. Then, the in-house developed Xtractor tool was used to
determine the intensity of each user-defined peak. This open
source tool generates uniform data (peak) arrays regardless of
spectral content (http://ms-utils.org/Xtractor/).
MALDI-TOF profiles were exported as DAT (.dat) files, all con-
taining m/z values with corresponding intensities.
Data processing and statistics
Mean of replicate spectra
The peak files generated by Xtractor were used for data analysis.
The mean of the remaining profiles of the quadruplicate spots
for the WCX purified samples was used. These processed profiles
will be further referred to as the WCX dataset.
For each ith patient, i = 1, . . ., n a set of spectral measurements
x1i = (x1i1, . . ., x1il) is collected from the WCX bead processed
samples such that the complete data may be represented by the
matrix
Sample processing
Blood
collection
1. Aliquotting and storage
2. WCX-Magnetic bead sample work up
3. Maldi spotting in quadruplicate
1. MALDI-TOF measurement
2. Baseline correction & alignment
3. Peak selection & -quantification
1. Mean of replicate spectra
2. Linear discriminant analysis with double cross validation
Profile pocessing
Data processing & statistics
Figure 1 Overview of the used workflow model of sample, profile,
data processing and statistics
Sample processing
1 Aliquotting and storage of the serum at -80°C until further
processing.
2 Automated fractionation of samples with Weak Cation Exchange
(WCX) magnetic beads (MB). Storage until measurement at
-80°C.
3 Automated spotting in quadruplicate on a matrix-assisted laser
desorption/ionization (MALDI) plate.
Profile processing
1 Measurements of MALDI plates in MALDI-time of flight (TOF).
2 Baseline correction and alignment of four profiles per samples,
removal of spectra without a signal owing to a spotting failure.
3 Selection of interesting peaks and extraction of this data with
Xtractor.
Data processing and statistics
1 Data analysis on mean of the remaining profiles.
2 Analysis of the profiles with linear discriminant analysis with
double-cross validation.
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with n = 160 and l = 113 (calibration set) represent the dimen-
sionality of the peak list. To complete the observed information on
individuals, we have the binary case–control outcome Y which
equals 1 for cases or 0 for controls36 (n = 50 cases, n = 110 con-
trols). The same procedure was performed for the validation set
with n = 114 and l = 113 (n = 39 cases, n = 75 controls).
Linear discriminant analysis
As previously described by Mertens et al.35 and de Noo et al.,25 a
double cross-validatory implementation of linear discriminant
analysis for the calibration of a diagnostic rule based on a single
(mean) spectrum per patient was performed. Each sample was
assigned to the group for which the probability was highest. For
each analysis error rate (Error), sensitivity, specificity and the area
under the curve (AUC) were calculated. The error rates are based
on sensitivity and specificity values, assuming a prior class prob-
ability of 0.5 for each group. The validation data were subse-
quently predicted from a single calibration of the discriminant on
the calibration data (based on the observed optima from the
double-cross-validatory analysis) and results were compared with
known disease status.
Receiver-operating characteristic (ROC) curves with the true
positive rate (sensitivity) are plotted in function of the false-
positive rate (1-specificity) for different cut-off points of a param-
eter. Each point on the ROC curve represents a sensitivity/
specificity pair corresponding to a particular decision threshold.
The area under the ROC curve (AUC) is a measure of how well
a parameter can distinguish between two diagnostic groups
(diseased/normal).
An independent Student’s t-test on the case–control calibration
data was performed on a selection of the most discriminating
peaks observed in the calibrated discriminant model on the cali-
bration data. A P-value of < 0.05 was considered as significant.
Subsequently, all analyses were repeated after an additional
internal standardization performed on the calibration and vali-
dation sets separately, using the mean of all spectra and standard
deviation (SD) such that the new data within each set is
obtained as
X i
X X
SD
i i
i
*^_ =
−
to minimize differences in peak intensities between the calibration
set and the validation set which may be caused by batch effects. It
should be noted that the above standardization does not affect
calibrations or results on the calibration data (but it does for any
predictive analysis, such as in double cross-validation or when
predicting the validation set), as linear discrimination is invariant
to the above standardization.
Results
Patients
Patient characteristics for each set are shown in Table 1. All
patients were diagnosed with adenocarcinoma of the pancreas.
The calibration set consisted of 50 pre-operative PC patients (n =
23 male, n = 27 female) with a median age of 66 years (range
41–80). The validation set consisted of 39 pre-operative PC
patients (17 male, 22 female), included with the same criteria as
the calibration set. The median age of this group was 63 years
(range 38–81).
The median age of the control group in the calibration set (n =
50 male, n = 60 female) was 63 years (range 44–80) and the
median age of the control group in the validation set (n = 27 male,
n = 48 female) was 46 years (range 21–75). No significant differ-
ence in the median ages of the cases and the controls in the
calibration set (P = 0.073) was seen. In the validation set a differ-
ence was observed with a P-value of <0.001.
In the calibration set, 12 (24%) patients had stage I, 24 (48%)
had stage II, 5 (10%) had stage III and 9 (18%) had stage IV. In the
validation set, 4 (10.3%) patients were classified as stage I, 24
(61.5%) as stage II, 2 (5.1%) as stage III and 9 (23.1%) as stage IV.
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Figure 2 An example of three of the selected peaks from the Weak Cation Exchange (WCX) fractionated sampling. On the x-axis m/z values
are shown, on the y-axis intensities. The peaks with a m/z of 2084, 2770 and 8393 were highlighted
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In 29 patients (32.6%) the tumour appeared irresectable during
surgery. In all other cases (n = 60) a pancreaticoduodenectomy
(65.2%) or a pancreatic tail resection (2.2%) was performed.
In total, five patients (5.7%) had an increased inherited risk for
developing PC. In four patients a P16-Leiden mutation (also
annotated as a 19-base pair deletion of exon 2 of the CDKN2A
gene) was found. One patient was a BRCA2 mutation carrier.
Statistical analysis
In total, 274 serum samples were processed with WCX MB and
MALDI-TOF profiles were obtained in quadruplicate, yielding
1096 WCX profiles. Only one sample was excluded from further
statistical analysis because of low-quality profiles (as a result of
failed sample workup or not optimal MALDI spotting).
Linear discriminant analysis with double cross-validation
resulted in an error of 0.2054, a sensitivity of 73% and a specificity
of 85% with an AUC of 0.90 (Table 2) Next, we selected a number
of most discriminating peaks, based on the fitted discriminant
weights from a single recalibration of the linear discriminant rule,
based on the observed optima from the previous double cross-
validatory analysis. We selected seven peaks with m/z values of
2084, 2178, 2770, 2899, 3096, 8760 and 8939. In Table 3 these
peaks are shown together with a two-sample t-test, the corre-
sponding pooled estimate of the population standard deviation,
P-value and confidence interval.
Subsequently, calculations after internal standardization were
repeated as previously described and using the above set of
selected peaks in the calibration set which gave an error rate of
0.12, a sensitivity of 84%, a specificity of 92% and an AUC of
0.932. However, this result is likely strongly biased because of the
absence of any validatory analysis and the preliminary peak selec-
tion. Adding double-cross validation to this analysis to reduce the
bias resulted in the final results of an error rate of 0.17, a sensi-
tivity of 78% and a specificity of 89% with an AUC of 0.897
(highlighted in blue). Next, the standardized validation data were
predicted, using the peak-selected calibration classification rule
on standardized calibration data, confirming our first findings;
which gave an error rate of 0.17, a sensitivity of 74%, a specificity
of 91% and an AUC of 0.893 (Table 2). ROC curves of both the
calibration as well as the validation set are shown in Fig. 3.
A correct classification was obtained for 38 out of 50 (76%) PC
patients in the calibration set. In Table 1 these classifications are
displayed per diagnosis and stage. Seventy-six per cent of the
correctly classified cases were diagnosed with an early stage of PC
(stage I and II). On the other hand, 29 (81%) of the 36 patients
with an early stage were correctly classified. In the validation set, a
correct classification was achieved for 29 of 39 (74%) patients.
Twenty-one of these patients (72%) were operated upon in an
early stage and 75% of the patients with an early stage were cor-
rectly classified. None of the two patients with stage 1A in the
validation set were correctly classified. This concerns one male,
aged 60 years, diagnosed with a grade 2, small, 17-mm adenocar-
cinoma of the pancreas and one female, aged 63 years, diagnosed
with a grade 1, small, 5-mm adenocarcinoma of the pancreas.
Table 1 Patient characteristics for the calibration and the validation set
Calibration set Validation set
Cases Controls Correct
classification
Cases Controls Correct
classification
N 50 110 39 75
Age median, years
(min – max)
65.8
(41–80)
63.0
(44–80)a
63.4
(38–81)
45.9
(21–75)b
Male 23 50 17 27
Female 27 60 22 48
Diagnosis
Adenocarcinoma 50 38 (76%) 39 29 (74%)
Stage
IA 7 6 (86%) 2 0 (0%)
IB 5 5 (100%) 2 1 (50%)
IIA 3 2 (67%) 3 2 (75%)
IIB 21 16 (76%)c 21 18 (86%)
III 5 3 (60%) 2 2 (100%)
IV 9 6 (67%) 9 6 (67%)
CA19-9 26 19 (73%) 20 14 (70%)
Positive 17 12 (71%) c 13 11 (85%)
Negative 9 7 (78%) 7 3 (43%)
aP = 0.073.
bP = 0.000.
cn = 1 missing as a result of a low-quality profile.
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Serum biomarker
As shown in Table 1, in the calibration set, for 26 (52%) patients a
pre-operative CA19-9 value was determined. This is compared
with 20 (51%) in the validation set.
In the calibration set 17 (65.4%) patients had an elevated
CA19-9 value. Nineteen (73%) patients were correctly classified
with protein profiling.When protein profiling was compared with
CA19-9, protein profiling correctly classified two (19 versus 17)
more than CA19-9. In nine (34.6%) patients CA19-9 was not
increased. Seven (78%) of these patients were correctly classified
by protein profiling. In total, protein profiling gives additional
information in nine (two and seven) cases.
In the validation set, 65% (n = 13) of the patients had an
elevated CA19-9 value. Fourteen (70%) of the 20 patients with a
known CA19-9 value were correctly classified. Protein profiling
was correctly classifying one (14 versus 13) more than CA19-9. In
seven (35%) patients CA19-9 was not increased. Three of these
patients (43%) were correctly classified. In total, in the validation
set, protein profiling gave additional information in four (one and
three) cases.
Patients with increased risk
Three of the five (60%) patients with an increased risk were cor-
rectly classified with protein profiling (two with a P16-Leiden
mutation, one with a BRCA2 mutation).
In three cases CA19-9 was known, two with elevated CA19-9
values. One of these patients was correctly classified with protein
profiling. One patient had no increased CA19-9 value. This
patient was incorrectly classified by protein profiling. Thus,
protein profiling gave additional information in one case.
Discussion
The accurate and early detection of PC may result in more
patients that could benefit from a pancreaticoduodenectomy and
may increase the survival time. Clinical proteomics has emerged
as a promising strategy to develop novel tools for biomarker
strategies.37–42
In this study, high-resolution MS profiling of human serum
was used, with the aim of detecting specific patterns present in
patients with PC. Using this method, a set of seven peptides was
found that differentiated PC from healthy volunteers with a
sensitivity of 78% and a specificity of 89%. These results were
successfully validated in an independent case–control group.
Although in several previous studies serum protein patterns
were found to show a high sensitivity and specificity as an early
diagnostic tool, critical notes have been made on biological vari-
ation, pre-analytical conditions and analytical reproducibility of
serum protein profiles.43 Thus, the application of proteomic
spectra can only be applied in a routine clinical setting when the
collection and processing of the data is subjected to stringent
quality control procedures.14,21,43 In the Leiden University
Medical Center, much effort has been spent in optimizing the
protocol for high throughput analysis. A completely robotized
and automated procedure was used for sample handling. This
protocol was tested with respect to the number of freeze-thaw
Table 2 Error, sensitivity, specificity and area under the curve (AUC) data in percentages from various analyses for the calibration and the
validation set
Data Calibration set Validation set
Original data
(113 peaks)
Selected
7 peaks
Selected
7 peaks
Original data
(113 peaks)
Selected
7 peaks
Double-cross validation Yes No Yes NA NA
Standardized No Yes Yes No Yes
Error % 21 12 17 23 17
Sensitivity % 73 84 78 59 74
Specificity % 85 92 89 95 91
AUC 0.895 0.932 0.897 0.94 0.893
The first column represents the double-cross validation results of the analysis on 113 peaks. In the second column the results from the standardized
data are shown without double-cross validation. The third column shows the most reliable results after standardization and double-cross validation.
The last two columns represent the validation data with and without standardization. Highlighted in bold are the two columns representing the
definitive data of the calibration set and the validation set.
NA, not applicable.
Table 3 The seven most discriminating peaks in Dalton with a
corresponding t-test value, standard deviation (SD), P-value and
95%- confidence interval
m/z value t-test SD P-value Confidence interval
2084 -3.7054 0.9674 0.00029* -0.9438 -0.2875
2178 -0.5519 0.8925 0.58179 -0.3874 0.2182
2770 -5.5234 0.8236 0.00014* -1.0607 -0.5019
2899 0.1172 0.7440 0.90683 -0.2374 0.2674
3096 -2.7116 0.7581 0.00744* -0.6103 -0.0959
8760 -1.2342 1.1477 0.21898 -0.6327 0.1461
8939 0.5841 1.0086 0.56002 -0.2410 0.4433
Significant peaks with a P-value <0.05 are marked with a *.
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cycles, the period between collection and serum centrifugation
and reproducibility.14
In principle, a high-end MS setup is sensitive enough to detect
almost any protein, but the true sensitivity of MS is modulated by
the nature of the sample. Biological samples are typically charac-
terized by a wide range of protein abundances, and mass spec-
trometers are not well equipped to deal with this wide dynamic
range. Peptides do not ionize with equal efficiency, potentially
putting some proteins at a disadvantage in terms of detection.
This issue is further complicated by low-molecular-weight pro-
teins and those expressed at low abundance. Sample fractionation
overcomes these issues, reduces the impact of undersampling and
improves the reproducibility between analyses.13 In the present
study,WCX magnetic beads were used with specific binding char-
acteristics. These magnetic beads can be well implemented in a
robotic platform for fully automated use and this automation
ensures the control of each step in the extraction protocol and
thus minimizes technical variability.20 In addition, this automa-
tion in combination with the high speed of data acquisition of
MALDI MS allows high-throughput analysis of thousands of
samples.
In 2007, Goonetilleke et al. published a systematic review about
CA19-9 as a diagnostic serum marker for PC. They calculated a
median sensitivity of 79% and a median specificity of 82%.44 With
the present protein profiling a comparable sensitivity but a higher
specificity was achieved. In 13 reports, CEA shows a mean sensi-
tivity of 54% and a specificity of 79%.
Other newer serum biomarkers described by Goonetilleke et al.
are carbohydrate antigen 242 (CA 242), carbohydrate antigen 50
(CA 50), SPAN-1 and sialyl-lcat-N-tetraose (DUPAN-2). These
newer biomarkers perform with sensitivities of 65–83% and spe-
cificities of 80–93%. Until now, none of these biomarkers are
clinically used.
In this study, CA19-9 was semi-routinely assessed with an
overall sensitivity of 65% and 63%, respectively. Although this
marker is not clinically used for the detection of early PC, we
choose to compare our profile with this ‘best currently available’
marker. Comparing the protein profiling classification with CA
19-9 values resulted in an improvement for 13 patients.
In the calibration set, 29 out of 36 patients (81%) with stage I
and II PC were correctly classified, whereas in the validation set
early PC was correctly classified in 21 out of 28 patients (75%).
Stage IA and IB differentiate between the tumour size of 2 cm.
Also for higher stages, the test showed a high sensitivity and spe-
cificity. In total, this gives a sensitivity of 78% for the detection of
early PC with our profile.
Nowadays, the emphasis in biomarker research has moved
towards peak identification, i.e. biomarker characterization. It is
convenient to first determine the diagnostic power of candidate
markers before performing identification studies and further
investigations into their biological role in disease mechanisms, as
identification of peptide- or protein signals in a profile is not
straight forward. Such efforts require specific separation- or
enrichment strategies and a high MS/MS data quality for identi-
fication of endogenous species, i.e. large coverage of fragment
ions. Until now, most reported identifications of serum peptides
in profiles were based on SELDI enrichment chips [i.e. Immobi-
lized Metal Affinity Capture (IMAC)34] or on Reversed Phase
(RP)C18 solid-phase extraction (SPE) procedures45–47 and can
therefore not directly be overlaid with WCX profiles. Only a few
peptide/protein identifications from WCX fractionation have
been reported.23,34
Previously, peaks in MALDI-TOF profiles at m/z’s of 2084,
2178, 2770, 2899, 8769 and 8939 have been characterized as frag-
ments of FGA-chain, Apo-CIII and Apo-CII45 Although thesem/z
values correspond with the seven most discriminating peaks of
this study, these characterizations have been performed after
RPC18 purification and are therefore not completely transposable
with our data. The latter peak of 8.9 kDa is also described in the
literature as Human Complement C3 (P01024, Unitprot.org), but
identified as a discriminating peptide after fractionation with
IMAC beads. Recently,Albrethsen et al.48 published an overview of
Figure 3 Receiever-opertaing characteristic (ROC) curves of the calibration and validation set after peak selection with standardization
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the MALDI and SELDI characterization of peptides and proteins,
but these m/z values did not correspond exactly with the seven
discriminating peaks of this study.
The present profile is not yet tested on individuals with an
increased risk (smoking, chronic pancreatitis and diabetes) of
developing PC or an increased inherited risk (carriers of a p16-
Leiden mutation, Peutz–Jeghers syndrome, FAMMM or BRCA2
mutation carriers). This group might especially benefit from a
highly sensitive and specific new biomarker. A retrospective series
will be analysed and the collection of serum during surveillance of
this high-risk group has been set up.
Furthermore the method should be further improved before it
is clinical applicable. The first step, which was presented in this
study, is that we can identify patients with pancreatic cancer
from healthy controls. However, the value of the test for high-risk
patients as patients with diabetes, smoking, pancreatitis and/or
other contributing factors is still unknown. A next step in our
research programme is to analyse the serum proteomics param-
eter in a group of patients with an increased risk for developing
PC (smoking, chronic pancreatitis and diabetes). Furthermore the
research continues to improve the cleaning up procedure using
two different MB, with promising preliminary results. This could
mean that sensitivity and specificity could be improved.
In conclusion, MS technology allows high throughput analysis
of peptides and proteins, with accurate results and, when properly
applied, with high reproducibility. Protein profiling can classify
pancreatic patients from healthy volunteers based on the SPE
fractionation with WCX MB. This promising new biomarker is a
simple, additional test for the diagnosis of PC in clinical practice.
Further research is necessary to evaluate its specificity.
Conflicts of interest
None declared.
Authors's contributions
We declare that all authors meet the following three conditions:
(1) substantial contributions to conception and design, or acquisition of
data, or analysis and interpretation of data;
(2) drafting the article or revising it critically for important intellectual content;
and
(3) final approval of the version to be published.
Acknowledgements
We greatly appreciate the help of Marco R. Bladergroen and Hans Dalebout
from the Biomolecular Mass Spectrometry unit of the Department of Parasi-
tology, Rob Keyzer, Gabi van Pelt and Ronald L. P. van Vlierberghe from the
laboratory of Surgery, Linda Verhoeff, Arienne K. Loor, Annemarie M.E.G.
Voet-van den Brink and Richard E. Zwaan from the datacenter of Surgery.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. (2011) Global
cancer statistics. CA Cancer J Clin 61:69–90.
2. Siegel R, Ward E, Brawley O, Jemal A. (2011) Cancer statistics, 2011: the
impact of eliminating socioeconomic and racial disparities on premature
cancer deaths. CA Cancer J Clin 61:212–236.
3. Wong T, Howes N, Threadgold J, Smart HL, Lombard MG, Gilmore I et al.
(2001) Molecular diagnosis of early pancreatic ductal adenocarcinoma in
high-risk patients. Pancreatology 1:486–509.
4. Sener SF, Fremgen A, Menck HR, Winchester DP. (1999) Pancreatic
cancer: a report of treatment and survival trends for 100,313 patients
diagnosed from 1985–1995, using the National Cancer Database. J Am
Coll Surg 189:1–7.
5. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y et al. (2005) The clinical
value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis
of pancreatic cancer. Eur J Surg Oncol 31:164–169.
6. Hruban RH, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ,
Falatko F et al. (1999) Familial pancreatic cancer. Ann Oncol 10 (Suppl.
4):69–73.
7. Schenk M, Schwartz AG, O`Neal E, Kinnard M, Greenson JK, Fryzek JP
et al. (2001) Familial risk of pancreatic cancer. J Natl Cancer Inst 93:640–
644.
8. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W.
(2000) Risk of developing pancreatic cancer in families with familial atypi-
cal multiple mole melanoma associated with a specific 19 deletion of p16
(p16-Leiden). Int J Cancer 87:809–811.
9. Werkgroep Klinische Oncogenetica. (1996) Erfelijke Tumoren: ‘Richtlijnen
voor Diagnostiek en Preventie’. zie ook. Available at http://www.stoet.nl/
uploads/richtlijnenboekje.pdf (last accessed 2010).
10. Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis
NA et al. (2011) Magnetic resonance imaging surveillance detects early-
stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroen-
terology 140:850–856.
11. Wulfkuhle JD, Liotta LA, Petricoin EF. (2003) Proteomic applications for
the early detection of cancer. Nat Rev Cancer 3:267–275.
12. Aebersold R, Mann M. (2003) Mass spectrometry-based proteomics.
Nature 422:198–207.
13. Nilsson T, Mann M, Aebersold R, Yates JR, III, Bairoch A, Bergeron JJ.
(2010) Mass spectrometry in high-throughput proteomics: ready for the
big time. Nat Methods 7:681–685.
14. de Noo ME, Tollenaar RA, Ozalp A, Kuppen PJ, Bladergroen MR, Eilers
PH et al. (2005) Reliability of human serum protein profiles generated with
C8 magnetic beads assisted MALDI-TOF mass spectrometry. Anal Chem
77:7232–7241.
15. Albrethsen J. (2007) Reproducibility in protein profiling by MALDI-TOF
mass spectrometry. Clin Chem 53:852–858.
16. Duncan MW, Aebersold R, Caprioli RM. (2010) The pros and cons of
peptide-centric proteomics. Nat Biotechnol 28:659–664.
17. Mauri P, Scigelova M. (2009) Multidimensional protein identification tech-
nology for clinical proteomic analysis. Clin Chem Lab Med 47:636–646.
18. Hu L, Ye M, Zou H. (2009) Recent advances in mass spectrometry-based
peptidome analysis. Expert Rev Proteomics 6:433–447.
19. Callesen AK, Mohammed S, Bunkenborg J, Kruse TA, Cold S, Mogensen
O et al. (2005) Serum protein profiling by miniaturized solid-phase extrac-
tion and matrix-assisted laser desorption/ionization mass spectrometry.
Rapid Commun Mass Spectrom 19:1578–1586.
20. Jimenez CR, El FZ, Knol JC, Hoekman K, Kruyt FA, Giaccone G et al.
(2007) Automated serum peptide profiling using novel magnetic C18
beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl 1:598–
604.
HPB 609
HPB 2013, 15, 602–610 © 2012 International Hepato-Pancreato-Biliary Association
21. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC
et al. (2004) Serum peptide profiling by magnetic particle-assisted, auto-
mated sample processing and MALDI-TOF mass spectrometry. Anal
Chem 76:1560–1570.
22. de Noo ME, Deelder A, van der Werff M, Ozalp A, Mertens B, Tollenaar R.
(2006) MALDI-TOF serum protein profiling for the detection of breast
cancer. Onkologie 29:501–506.
23. Alagaratnam S, Mertens BJ, Dalebout JC, Deelder AM, van Ommen GJ,
den Dunnen JT et al. (2008) Serum protein profiling in mice: identification
of factor XIIIa as a potential biomarker for muscular dystrophy. Proteom-
ics 8:1552–1563.
24. Nadarajah VD, Mertens BJA, Dalebout H, Bladergroen M, Alagaratnam S,
Bushby K et al. (2012) Serum peptide profiles of Duchenne Muscular
Dystrophy (DMD) patients evaluated by data handling strategies for high
resolution content. J Proteomics Bioinf 5:96–103.
25. de Noo ME, Mertens BJ, Ozalp A, Bladergroen MR, van der Werff MP, van
de Velde CJ et al. (2006) Detection of colorectal cancer using MALDI-TOF
serum protein profiling. Eur J Cancer 42:1068–1076.
26. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM
et al. (2002) Use of proteomic patterns in serum to identify ovarian
cancer. Lancet 359:572–577.
27. Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L et al.
(2009) Pancreatic cancer biomarkers discovery by surface-enhanced
laser desorption and ionization time-of-flight mass spectrometry. Clin
Chem Lab Med 47:713–723.
28. Sun ZL, Zhu Y, Wang FQ, Chen R, Peng T, Fan ZN et al. (2007) Serum
proteomic-based analysis of pancreatic carcinoma for the identification
of potential cancer biomarkers. Biochim Biophys Acta 1774:764–771.
29. Kakisaka T, Kondo T, Okano T, Fujii K, Honda K, Endo M et al. (2007)
Plasma proteomics of pancreatic cancer patients by multi-dimensional
liquid chromatography and two-dimensional difference gel electrophore-
sis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in
pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 852:
257–267.
30. Deng R, Lu Z, Chen Y, Zhou L, Lu X. (2007) Plasma proteomic analysis of
pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas
34:310–317.
31. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke
S et al. (2007) Identification of potential markers for the detection of
pancreatic cancer through comparative serum protein expression profil-
ing. Pancreas 34:205–214.
32. Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S et al.
(2005) Possible detection of pancreatic cancer by plasma protein profil-
ing. Cancer Res 65:10613–10622.
33. Yu KH, Rustgi AK, Blair IA. (2005) Characterization of proteins in human
pancreatic cancer serum using differential gel electrophoresis and
tandem mass spectrometry. J Proteome Res 4:1742–1751.
34. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S
et al. (2004) Serum diagnosis of pancreatic adenocarcinoma using
surface-enhanced laser desorption and ionization mass spectrometry.
Clin Cancer Res 10:860–868.
35. Mertens BJ, de Noo ME, Tollenaar RA, Deelder AM. (2006) Mass spec-
trometry proteomic diagnosis: enacting the double cross-validatory para-
digm. J Comput Biol 13:1591–1605.
36. Mertens BJA, Burgt van der YEM, Velstra B, Mesker WE, Deelder AM,
Tollenaar RAEM. (2011) On the use of double cross-validation for the
combination of proteomic mass spectral data for enhanced diagnosis
and prediction. Stat Probab Lett 81:759–766.
37. Zapico-Muniz E, Farre-Viladrich A, Rico-Santana N, Gonzalez-Sastre F,
Mora-Brugues J. (2010) Standardized peptidome profiling of human
serum for the detection of pancreatic cancer. Pancreas 39:1293–1298.
38. Cecconi D, Palmieri M, Donadelli M. (2011) Proteomics in pancreatic
cancer research. Proteomics 11:816–828.
39. Pawa N, Wright JM, Arulampalam TH. (2010) Mass spectrometry based
proteomic profiling for pancreatic cancer. JOP 11:423–426.
40. Chen JH, Ni RZ, Xiao MB, Guo JG, Zhou JW. (2009) Comparative pro-
teomic analysis of differentially expressed proteins in human pancreatic
cancer tissue. Hepatobiliary Pancreat Dis Int 8:193–200.
41. Liu D, Cao L, Yu J, Que R, Jiang W, Zhou Y et al. (2009) Diagnosis of
pancreatic adenocarcinoma using protein chip technology. Pancreatol-
ogy 9:127–135.
42. Guo J, Wang W, Liao P, Lou W, Ji Y, Zhang C et al. (2009) Identification
of serum biomarkers for pancreatic adenocarcinoma by proteomic analy-
sis. Cancer Sci 100:2292–2301.
43. Diamandis EP. (2004) Analysis of serum proteomic patterns for early
cancer diagnosis: drawing attention to potential problems. J Natl Cancer
Inst 96:353–356.
44. Goonetilleke KS, Siriwardena AK. (2007) Systematic review of carbohy-
drate antigen (CA 19-9) as a biochemical marker in the diagnosis of
pancreatic cancer. Eur J Surg Oncol 33:266–270.
45. Tiss A, Smith C, Menon U, Jacobs I, Timms JF, Cramer R. (2010) A
well-characterised peak identification list of MALDI MS profile peaks for
human blood serum. Proteomics 10:3388–3392.
46. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H,
Olshen AB et al. (2006) Differential exoprotease activities confer
tumor-specific serum peptidome patterns. J Clin Invest 116:271–
284.
47. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ et al.
(2005) Plasma protein profiling for diagnosis of pancreatic cancer
reveals the presence of host response proteins. Clin Cancer Res
11:1110–1118.
48. Albrethsen J. (2011) The first decade of MALDI protein profiling:
a lesson in translational biomarker research. J Proteomics 74:765–
773.
610 HPB
HPB 2013, 15, 602–610 © 2012 International Hepato-Pancreato-Biliary Association
